
Shaily Engineering Plastics (Q4 & FY26) 1/10 While the market argues over which pharma giant wins the obesity war, one Indian company quietly became the thing that delivers the drug. FY26 was the year Shaily's semaglutide pens went live — commercially launched in Canada, first-ever US tentative approval, EMA nod for Teriparatide. Revenue ₹991 Cr (+26%) | PAT ₹170 Cr (+83%) | Healthcare mix 21% → 40% in twelve months. The picks-and-shovels thesis just got real. 🧵









